Bariatric surgery outperforms medical therapy for T2D across income levels

Nonmedical factors drive up to 60 percent of health outcomes, and for people with type 2 diabetes (T2D), social determinants of health factors like poverty, food insecurity, and unstable housing can derail even the best treatment plans. Now, a long-term study led by investigators at Joslin Diabetes Center finds that bariatric metabolic surgery is more effective at glycaemic and weight control than medical and lifestyle interventions for people with T2D, even in the setting of social vulnerability.

"Our randomised study allowed us to explore the influence of social deprivation on the comparative efficacy of surgical versus medical therapy," said Dr Mary Elizabeth Patti, a senior investigator at Joslin and a professor of medicine at Harvard Medical School. "The marked advantage of surgery over medical therapy was seen in populations with both high and low social vulnerability over the long term."

The findings come from analysis of the ARMMS-T2D study (Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes), a landmark collaboration that pooled data from four independent U.S. clinical trials to compare the long-term effectiveness of bariatric metabolic surgery against medical and lifestyle interventions for people with type 2 diabetes and obesity. (Notably, while the medical interventions did include GLP-1 receptor medications, the study was conducted before the more potent versions were available.) With up to 12 years of follow-up on 262 participants, ARMMS-T2D represents the largest and longest analysis of its kind.

"ARMMS-T2D is the largest and longest study comparing metabolic surgery to medical therapy for type 2 diabetes, and these results send a clear message: surgery delivers durable benefits in glycaemic control and weight loss regardless of a patient's socioeconomic background," said Dr John Kirwan, Director of the Integrated Physiology and Molecular Medicine Laboratory at Pennington Biomedical Research Center. "As a consortium, we've now shown across 12 years of follow-up that metabolic surgery can change the trajectory of this disease for diverse patient populations. That's exactly the kind of evidence clinicians and patients need to make confident treatment decisions."

Social determinants of health are increasingly recognized as powerful drivers of chronic disease outcomes. Previous reports from the consortium established that bariatric metabolic surgery produces superior long-term blood sugar control compared to medical management for patients with type 2 diabetes, with higher rates of diabetes remission and reduced need for diabetes medications. The current study extends that work by examining whether social vulnerability - measured using factors like income, education and housing - affects patients' response to each treatment approach.

Patti and colleagues stratified participants by social vulnerability using the Area Deprivation Index, a measure that accounts for factors like income, education, housing, and employment at the neighbourhood level. They found that bariatric metabolic surgery produced greater improvements in blood sugar control and weight loss than medical and lifestyle interventions in both high- and low-vulnerability groups.

The findings could have implications for how clinicians counsel patients about treatment options and how health systems allocate resources. While bariatric surgery improved outcomes across all socioeconomic groups, more vulnerable patients still had worse glycaemic control and less weight loss than their more advantaged peers. The researchers note that future studies will need to explore why, and whether factors like food insecurity, limited health literacy, or reduced access to medications and physical activity help explain the gap.

"This study underscores the powerful role that metabolic/bariatric surgery can play in reshaping the long-term trajectory of type 2 diabetes," said Dr Phil Schauer, Director of the Metamor Institute at Pennington Biomedical. "Our collaborative work with Joslin and other institutions as part of the ARMMS-T2D study demonstrates that surgical interventions are not just effective in academic trials, but can deliver meaningful benefits across broad patient groups - offering hope and improved health for those most affected by this disease."

"We did not detect statistically significant differences in the comparative advantage of surgery over medical therapy by ADI," the authors write. "Associations were stronger for the medical treatment group, suggesting that social vulnerability may modify outcomes, particularly when the ongoing need for medical therapy for diabetes and obesity is greater.”

The finding were featured in the paper, ‘Effect of Social Vulnerability on Efficacy of Bariatric Surgery Versus Medical and Lifestyle Intervention for Type 2 Diabetes: Analysis of the ARMMS-T2D Consortium of Randomized Trials’, published in the Annals of Internal Medicine. To access this paper, please click here (log-in maybe required)